Akademik Veri Yönetim Sistemi
83rd FIP World Congress of Pharmacy and Pharmaceutical Sciences, Kobenhavn, Danimarka, 31 Ağustos - 03 Eylül 2025, cilt.25, sa.4, ss.18-19, (Özet Bildiri)
Background: Neuropathic pain is a type of chronic pain resulting from a lesion or disease of the somatosensory nervous system's primary afferent neurons (Shinu et al.,2022). Medications used in the treatment of neuropathic pain often cause adverse effects. Additionally, since many patients suffering from this condition belong to the geriatric population, have polypharmacy issues, and present with comorbid diseases, these adverse effects can become moresevere (Baron, 2009). Due to these challenges, neuropathic pain management is difficult, and in some cases, combination therapies may offer greater efficacy (Kerstman et al., 2013). Furthermore, plant-derived medications are considered alternative treatments and are widely used for various conditions such as pain and inflammation with minimal or no side effects (Hasnat et al., 2024).
Purpose: This study aims to evaluate the anti-allodynic effects of rutin at doses of 25, 50, and 100 mg/kg, both alone and in combination with 3 mg/kg pregabalin, in a chronic constriction injury (CCI)-induced neuropathic pain model in rats.
Material and Method: To induce neuropathic pain, the nerves of rats were ligated using the chronic constriction injury (CCI) model. Rutin was administered orally at the doses of 25, 50 and 100 mg/kg, both alone and in combination with pregabalin at 3 mg/kg at 30-180 min. time interval. Pain thresholds of the rats were assessed using the von Frey devices.
Results: The combination of 25 mg and 50 mg doses of rutin produced be the higher efficacy in the 60-120 min. interval compared to 30 mg pregabalin. The efficacy of all combination groups was found to be significantly greater at certain time intervals compared to the groups with only rutin or the 3 mg pregabalin group. It was observed that the antiallodynic effect of the combination of 25 mg rutin was significant in the 30-180 min interval compared to 3 mgpregabalin, and the leading combination was the 25 mg group.
Discussion: This study demonstrated that the rutin-pregabalin combination holds potential for relieving neuropathic pain.The low-dose rutin-pregabalincombination, through their synergistic interaction, shortened the onset time of the antiallodynic effect, increased efficiency, and prolonged the duration of the effect.